Exploration of Medicine

Table 14

Prostate cancer, effect of cannabinoids in animal models

Disease model	Treatment	Comparator	Results	Ref.
2 prostate cancer cell lines (LNCaP, DU-145), s.c. xenografts, athymic nude mice; 6 groups for each cell line	CBD-E (~65% CBD) 1 or 10 or 100 mg/kg i.p. daily; Initiated D15, terminated D38	Docetaxel 5 mg/kg, i.v. once weekly; Bicalutamide 25–50 mg/kg p.o. 3 times per week; CBD-E 100 mg/kg per day i.p. plus either docetaxel 5 mg/kg i.v. once weekly, or bicalutamide 25–50 mg/kg p.o. 3 times per week	CBD-E (extract) dose-dependently inhibited the growth of xenografts from LNCaP (AR+), but not from DU-145 (AR–) cells; CBD-E potentiated docetaxel/taxotere effects in DU-145, less so in LNCaP xenografts; CBD-E enhanced efficacy of bicalutamide on LNCaP only at the highest concentration tested (100 mg/kg i.p.); A group receiving pure CBD was not included	[139]
Prostate cancer, BALB/c nude mice, s.c. PC3-xenograft (AR–)	CBD (150 mg/kg per day), injected peri-tumoral for 10 days combined with siRBBp6 gene therapy (RBBp6 antibodies)	Cisplatin (50 mg/kg per day), Cannabis sativa extract (200 mg/kg per day) or vehicle	Tumour sizes were reduced with CBD and cisplatin by approximately 90% and significantly more than by the cannabis extract	[140]

Disease model

Treatment

Comparator

Results

Ref.

2 prostate cancer cell lines (LNCaP, DU-145), s.c. xenografts, athymic nude mice;

6 groups for each cell line

CBD-E

(~65% CBD)

1 or 10 or 100 mg/kg i.p. daily;

Initiated D15, terminated D38

Docetaxel 5 mg/kg, i.v. once weekly;

Bicalutamide 25–50 mg/kg p.o. 3 times per week;

CBD-E 100 mg/kg per day i.p. plus either docetaxel 5 mg/kg i.v. once weekly, or bicalutamide 25–50 mg/kg p.o. 3 times per week

CBD-E (extract) dose-dependently inhibited the growth of xenografts from LNCaP (AR+), but not from DU-145 (AR–) cells;

CBD-E potentiated docetaxel/taxotere effects in DU-145, less so in LNCaP xenografts;

CBD-E enhanced efficacy of bicalutamide on LNCaP only at the highest concentration tested (100 mg/kg i.p.);

A group receiving pure CBD was not included

Prostate cancer, BALB/c nude mice, s.c. PC3-xenograft (AR–)

CBD (150 mg/kg per day), injected peri-tumoral for 10 days combined with siRBBp6 gene therapy (RBBp6 antibodies)

Cisplatin (50 mg/kg per day), Cannabis sativa extract (200 mg/kg per day) or vehicle

Tumour sizes were reduced with CBD and cisplatin by approximately 90% and significantly more than by the cannabis extract

CBD-E: CBD-extract (synonym: CBD-BDS, CBD botanical drug substance); p.o.: per os; i.v.: intravenous injection